|The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial …|
PJ Hesketh, SM Grunberg, RJ Gralla, DG Warr, F Roila, R De Wit, ...
Journal of Clinical Oncology 21 (22), 4112-4119, 2003
|Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting: results from a …|
S Poli‐Bigelli, J Rodrigues‐Pereira, AD Carides, G Julie Ma, K Eldridge, ...
Cancer 97 (12), 3090-3098, 2003
|Reduction of cisplatin-induced emesis by a selective neurokinin-1–receptor antagonist|
RM Navari, RR Reinhardt, RJ Gralla, MG Kris, PJ Hesketh, A Khojasteh, ...
New England Journal of Medicine 340 (3), 190-195, 1999
|Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists|
PJ Hesketh, S Van Belle, M Aapro, FD Tattersall, RJ Naylor, ...
European journal of cancer 39 (8), 1074-1080, 2003
|Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone|
D Campos, JR Pereira, RR Reinhardt, C Carracedo, S Poli, C Vogel, ...
Journal of clinical oncology 19 (6), 1759-1767, 2001
|Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized …|
BL Rapoport, K Jordan, JA Boice, A Taylor, C Brown, JS Hardwick, ...
Supportive Care in Cancer 18 (4), 423-431, 2010
|Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting|
SP Chawla, SM Grunberg, RJ Gralla, PJ Hesketh, C Rittenberg, ME Elmer, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2003
|Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial|
JS Solomkin, AE Yellin, OD Rotstein, NV Christou, EP Dellinger, ...
Annals of surgery 237 (2), 235, 2003
|Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist|
BJ Kopp, M Mrsan, BL Erstad, JJ Duby
American Journal of Health-System Pharmacy 64 (23), 2483-2487, 2007
|Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE|
S Grunberg, D Chua, A Maru, J Dinis, S DeVandry, JA Boice, JS Hardwick, ...
Journal of Clinical Oncology 29 (11), 1495-1501, 2011
|A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting|
TJ Gan, CC Apfel, A Kovac, BK Philip, N Singla, H Minkowitz, AS Habib, ...
Anesthesia & Analgesia 104 (5), 1082-1089, 2007
|Addition of the Oral NK1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin …|
R De Wit, J Herrstedt, B Rapoport, AD Carides, G Carides, M Elmer, ...
Journal of clinical oncology 21 (22), 4105-4111, 2003
|The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a …|
R de Wit, J Herrstedt, B Rapoport, AD Carides, J Guoguang-Ma, M Elmer, ...
European Journal of Cancer 40 (3), 403-410, 2004
|The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo …|
DG Warr, SM Grunberg, RJ Gralla, PJ Hesketh, F Roila, R De Wit, ...
European Journal of Cancer 41 (9), 1278-1285, 2005
|Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients …|
PJ Hesketh, M Aapro, JC Street, AD Carides
Supportive care in cancer 18 (9), 1171-1177, 2010
|Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869: a randomized controlled trial|
S Van Belle, MR Lichinitser, RM Navari, AM Garin, MLA Decramer, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2002
|Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind Phase III trial in patients undergoing open …|
P Diemunsch, TJ Gan, BK Philip, MJ Girao, L Eberhart, MG Irwin, J Pueyo, ...
British journal of anaesthesia 99 (2), 202-211, 2007
|Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis|
V Cocquyt, S Van Belle, RR Reinhardt, MLA Decramer, M O'brien, ...
European journal of cancer 37 (7), 835-842, 2001
|Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial|
YC Cohen, KS Liu, NL Heyden, AD Carides, KM Anderson, AG Daifotis, ...
Journal of the National Cancer Institute 99 (18), 1366-1374, 2007
|Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia|
S Shahinfar, RL Simpson, AD Carides, B Thiyagarajan, Y Nakagawa, ...
Kidney international 56 (5), 1879-1885, 1999